GE HealthCare Targets $70.9B Point-of-Care Market with AI-Powered Bedside MRI Precision
GE HealthCare is advancing portable, AI-powered diagnostic solutions that deliver hospital-grade MRI precision at the bedside, reducing facility overhead and improving patient outcomes. Point-of-care diagnostics are projected at $70.92 billion by 2032, and the CMS ACCESS Model starts in July 2026 to reward outcome-based care and spur software-defined imaging adoption.
1. AI-Driven Clinical Intelligence Fuels Imaging Leadership
GE HealthCare is accelerating its push into point-of-care diagnostics with AI-driven clinical intelligence platforms that replicate MRI-grade precision at the bedside. The company’s mobile MRI and ultrasound systems, enhanced by deep-learning reconstruction algorithms, have been deployed in over 350 hospitals worldwide since early 2024. Industry forecasts project the point-of-care diagnostics market to expand from $22.5 billion in 2023 to $70.92 billion by 2032, and GE HealthCare aims to capture a leading share through ongoing software upgrades and subscription-based analytics services.
2. CMS ACCESS Model to Boost Outcome-Based Reimbursement
Starting July 2026, the Centers for Medicare & Medicaid Services will launch the ACCESS Model, which ties reimbursement to clinical outcomes rather than volume. GE HealthCare has pre-registered over 1,200 outpatient clinics for the new program, offering its Edison AI platform to help customers meet performance benchmarks. Internal estimates suggest that meeting ACCESS thresholds could generate an incremental $250 million in annual revenue for GE HealthCare’s software-defined imaging business by FY 2028.
3. Strong Positioning Across Imaging, Monitoring and Diagnostics
GE HealthCare’s broad portfolio—from stationary MRI systems to portable, AI-powered scanners—underpins its robust positioning in medical imaging, patient monitoring and pharmaceutical diagnostics. In fiscal 2023, imaging segment revenue reached $19 billion, up 7% year-over-year, while monitoring solutions grew 9% driven by telemetry and critical-care software deployments. The company also reported a 12% rise in pharmaceutical diagnostics sales as demand climbs for companion diagnostics in oncology and rare diseases.
4. Weekly Options Opportunity Draws Investor Interest
With volatility in healthcare equities moderating, GE HealthCare’s weekly options have emerged as an attractive strategy for investors seeking leverage around upcoming product launches. Open interest on near-term calls surged by 35% over the past month, as traders anticipate pipeline announcements at the upcoming RSNA conference in December. Institutional data show that hedge funds have established net-long positions equivalent to 4 million shares, signaling confidence in near-term catalysts.